Minnesota Senate Bill SF2815

Minnesota 2025-2026 Regular Session

• Introduced: 3/20/25
• Refer: 3/20/25
• Refer: 4/7/25

Caption

Quarterly pharmacy tax refunds establishment

Impact

If enacted, SF2815 would amend existing tax regulations to formalize the quarterly refund mechanism, allowing pharmacies to better manage their cash flow by recovering taxes in a timely manner. The bill specifies time frames for pharmacies to apply for these refunds based on the quarters in which the drugs are delivered. This could significantly impact the operational strategies of pharmacies, encouraging them to expand their distribution beyond Minnesota while providing them with a financial incentive to do so. The bill’s provisions could potentially increase access to medications for residents in neighboring states, as pharmacies may be able to offer competitive pricing due to reduced tax burdens.

Summary

Senate File 2815 (SF2815) proposes amendments to Minnesota Statutes regarding pharmacy taxes, specifically to establish a quarterly refund process for pharmacies claiming taxes related to legend drugs delivered outside the state. This bill aims to enable pharmacies to recoup certain taxes they pay to wholesale distributors if those drugs are sold outside of Minnesota, thereby lightening the financial burden on these healthcare providers. The refunds are designed to equal the amount paid in taxes on these legend drugs delivered outside the state, which supports the financial viability of pharmacies dealing in a nationwide market.

Contention

Discussion around SF2815 will likely center on the implications of tax refunds on the state budget. Advocates for the bill may argue that it essential for incentivizing local pharmacies to engage in broader distribution, ultimately supporting healthcare accessibility. However, there may be concerns about the potential loss of tax revenue from the state’s budget, particularly if a significant number of pharmacies utilize these new refund provisions. Stakeholders including healthcare advocates, pharmacy associations, and tax policy experts might present varying perspectives on the long-term effects of the bill on both pharmacies and state finances.